Current NB risk stratification is mainly based on an assessment of clinical data, tumor histology, and genetic aberrations, such as MYCN-amplification (20% of all NB and 50% of high-risk NB) and 11q aberrations (20–45% of all NB) [3, 4]. Here, MYCN is linked to neuroblastoma.